Abpro Holdings (ABPO) is a clinical-stage biotechnology company focused on developing antibody therapeutics for severe and life-threatening diseases. The company generates no product revenue and had $0 in total revenue for the fiscal year ended December 31, 2025, down from $183 thousand in research and development services revenue in FY2024. Abpro's two lead product candidates, ABP-102 and ABP-201, are built on its proprietary tetravalent TetraBi antibody format, which binds two distinct targets with two binding sites per target. ABP-102 is designed to redirect T cells to fight cancer by co-targeting human epidermal growth factor receptor. The company funds operations through equity and debt financings, including convertible notes and a Standby Equity Purchase Agreement (SEPA). Management disclosed substantial doubt about the company's ability to continue as a going concern within one year of the FY2025 financial statement issuance date. Operating expenses totaled $8.5 million in FY2025, consisting of $989 thousand in R&D and $7.5 million in general and administrative costs.

Revenue model

No product revenue as of FY2025. Historical revenue consisted solely of research and development services fees ($183 thousand in FY2024, $0 in FY2025). The company finances operations through equity issuances, convertible notes, and seeks future revenue from collaboration agreements and research grants.

Products and services

Two lead product candidates: ABP-102 and ABP-201, both using the proprietary TetraBi tetravalent antibody format that binds two different targets with two distinct binding sites per target. ABP-102 targets cancer via T-cell redirection through co-targeting of human epidermal growth factor receptor.

Customers and end markets

No commercial customers as of FY2025. End market is oncology and severe disease therapeutics, subject to FDA regulatory approval prior to any commercialization.

Value-chain role

Pre-commercial drug developer. Relies on third-party manufacturers for any future product manufacturing. Subject to FDA oversight including cGMP compliance requirements at manufacturing facilities.

Geographic exposure

Operations based in the United States. Seeks FDA approval domestically; filing references potential foreign jurisdiction regulatory approvals as a future consideration.

Source: SEC 10-K, filed 2026-04-15

Industry: Biological Products, (No Diagnostic Substances)